Advanced Biomed Inc. (ADVB) Income Statement
ADVB FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsADVB revenue and net income
Where ADVB's revenue goes
FY2026Each bar shows an amount and its share of revenue. ADVB kept 162,380.3% of revenue as net income.
ADVB profit margins
ADVB growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ADVB quarterly EPS vs estimates
Next report: November 18, 2026.
ADVB income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | $4,112 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $10,711 | $12,550 | $11,890 | $4,477 | $2,031 |
| Gross profit | — | −$10,711 | −$12,550 | −$11,890 | −$4,477 | −$2,031 |
| Research & development | — | $28,341 | $880,193 | $45,029 | $1.6M | $1.7M |
| Sales, general & admin | $4.6M | $2.1M | $1.3M | $1.3M | $624,774 | $44,470 |
| Total operating expenses | $204,974 | $83,401 | $2.5M | $88,094 | $2.4M | $1.8M |
| Operating income | −$200,861 | −$94,112 | −$2.5M | −$99,984 | −$2.4M | −$1.8M |
| Interest income | — | — | $53,495 | $21,402 | $243 | $28 |
| Interest expense | $226 | — | — | — | — | — |
| Income before taxes | −$201,794 | −$101,524 | −$2.8M | −$121,521 | −$4.0M | −$1.8M |
| Income taxes | −$12.9M | — | — | — | — | — |
| Net income | $6.7M | −$101,524 | −$2.8M | −$121,521 | −$4.0M | −$1.8M |
| EBITDA | −$6.3M | −$83,401 | −$2.1M | $265,247 | −$2.2M | −$1.8M |
| EPS (diluted) | $0.18 | −$0.09 | −$2.57 | −$0.11 | −$3.72 | — |
| Operating margin | −4,884.8% | — | — | — | — | — |
| Net margin | 162,380.3% | — | — | — | — | — |
| Sep '26 | Mar '26 | Dec '25 | Sep '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4,037 | $0 | $0 | $17,200 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $295 | $466 | $2,085 | $680 | — | $3,162 | — | $2,375 | $2,812 | $2,817 | $5,436 |
| Gross profit | — | −$294 | −$466 | −$2,085 | −$680 | — | −$3,162 | — | −$2,375 | −$2,812 | −$2,817 | −$5,436 |
| Research & development | — | $243,226 | $6,003 | $235,992 | $250,462 | $212,397 | $181,703 | $209,112 | $7,615 | $188,387 | $169,185 | $488,170 |
| Sales, general & admin | — | $276,610 | $210,311 | $260,603 | $438,769 | $67,667 | $311,032 | $177,008 | $404,738 | $435,904 | $244,127 | $498,465 |
| Total operating expenses | $180,775 | $519,836 | $12,313 | $523,914 | $762,739 | $280,064 | $520,027 | $704,613 | $20,814 | $651,302 | $440,245 | $1.0M |
| Operating income | −$176,738 | −$519,836 | −$12,778 | −$523,914 | −$762,739 | −$280,064 | −$520,027 | −$704,613 | −$23,190 | −$651,302 | −$440,245 | −$1.0M |
| Interest income | — | — | $9,206 | $448 | $0 | $15,377 | $10 | $33,411 | $104 | $19,966 | $14 | $21,280 |
| Interest expense | $510 | $112 | — | — | — | — | — | — | — | — | — | — |
| Income before taxes | $448,454 | −$488,942 | $225,595 | −$386,901 | −$1.4M | −$579,494 | −$265,580 | −$809,386 | −$42,075 | −$145,345 | −$771,316 | −$1.7M |
| Income taxes | −$38 | — | $144,257 | — | — | — | — | — | — | — | — | — |
| Net income | −$429,969 | −$488,942 | $220,947 | −$386,901 | −$1.4M | −$907,904 | −$265,580 | −$809,386 | −$42,075 | −$145,345 | −$771,316 | −$1.7M |
| EBITDA | −$176,738 | −$479,504 | −$12,312 | −$475,922 | −$528,769 | −$280,064 | −$417,809 | −$386,120 | −$39,694 | −$577,936 | −$350,936 | −$852,180 |
| EPS (diluted) | — | −$0.01 | $0.20 | −$0.03 | −$0.07 | — | — | — | — | — | — | — |
| Gross margin | — | — | — | −12.1% | — | — | — | — | — | — | — | — |
| Operating margin | −4,378.0% | — | — | −3,046.0% | — | — | — | — | — | — | — | — |
| Net margin | −10,650.7% | — | — | −2,249.4% | — | — | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ADVB's financial statements (latest annual report filed October 13, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ADVB financial results
In fiscal year 2026 (ended June 30, 2026), Advanced Biomed reported revenue of $0.0 million. It had net income of $6.7 million, a net profit margin of 162,380.3%. Diluted earnings per share came to $0.18.
See the ADVB stock overview for the latest quote and news, or the ADVB chart for price history and technical indicators.
ADVB income statement FAQ
What is Advanced Biomed's annual revenue?
Advanced Biomed reported total revenue of $0.0 million for fiscal year 2026, which ended on June 30, 2026.
Is Advanced Biomed profitable?
Yes. Advanced Biomed reported net income of $6.7 million in fiscal 2026, a net profit margin of 162,380.3%; its operating margin was −4,884.8%.
What are Advanced Biomed's earnings per share?
Advanced Biomed earned $0.18 per diluted share in fiscal 2026, compared with $-0.09 a year earlier.
When will Advanced Biomed report its next earnings?
Advanced Biomed is expected to report results for the quarter ending September 30, 2026 on November 18, 2026.
When does Advanced Biomed's fiscal year end?
Advanced Biomed's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on October 13, 2026.